1 – 50 of 72
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma : Real-world evidence from Sweden
(
- Contribution to journal › Article
-
Mark
Large differencies in age-specific survival in multiple myeloma in the nordic countries
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Deciphering the genetics and mechanisms of predisposition to multiple myeloma
(
- Contribution to journal › Article
-
Mark
Genome-wide CRISPR/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy
2024) In European Journal of Haematology(
- Contribution to journal › Article
- 2023
-
Mark
Computed tomography with adjusted dose for body mass index may be superior to whole-body radiography especially in elderly patients with multiple myeloma
(
- Contribution to journal › Article
-
Mark
Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real-world Swedish population receiving modern treatment
(
- Contribution to journal › Article
- 2022
-
Mark
Regional differences in treatment and outcome for myeloma patients in Sweden : A population based Swedish myeloma register study
(
- Contribution to journal › Article
-
Mark
Suppression of T-Cell Proliferation by Normal Density Granulocytes Led to CD183 Downregulation and Cytokine Inhibition in T-Cells
(
- Contribution to journal › Article
-
Mark
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
(
- Contribution to journal › Article
- 2021
-
Mark
Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Bone Marrow Neutrophils of Multiple Myeloma Patients Exhibit Myeloid-Derived Suppressor Cell Activity
(
- Contribution to journal › Article
-
Mark
Germline variants at SOHLH2 influence multiple myeloma risk
(
- Contribution to journal › Article
- 2020
-
Mark
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
(
- Contribution to journal › Article
-
Mark
Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry
(
- Contribution to journal › Article
-
Mark
Genetic predisposition for multiple myeloma
(
- Contribution to journal › Scientific review
-
Mark
Search for multiple myeloma risk factors using Mendelian randomization
(
- Contribution to journal › Article
-
Mark
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study
(
- Contribution to journal › Article
-
Mark
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma : The HOVON-87/NMSG-18 trial
(
- Contribution to journal › Article
- 2019
-
Mark
Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis
(
- Contribution to journal › Article
-
Mark
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
(
- Contribution to journal › Article
-
Mark
Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden
(
- Contribution to journal › Letter
-
Mark
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes
(
- Contribution to journal › Article
-
Mark
Exposure levels from radiology procedures used in myeloma diagnostics
(
- Contribution to journal › Published meeting abstract
- 2018
-
Mark
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma
(
- Contribution to journal › Article
-
Mark
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
(
- Contribution to journal › Article
-
Mark
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
(
- Contribution to journal › Article
-
Mark
Bone marrow eosinophils in plasma cell disorders
(
- Contribution to journal › Article
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
(
- Contribution to journal › Article
-
Mark
Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia
(
- Contribution to journal › Article
-
Mark
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
(
- Contribution to journal › Article
- 2017
-
Mark
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
(
- Contribution to journal › Article
-
Mark
Direct evidence for a polygenic etiology in familial multiple myeloma
(
- Contribution to journal › Article
-
Mark
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
(
- Contribution to journal › Article
-
Mark
NOX2-dependent immunosuppression in chronic myelomonocytic leukemia
(
- Contribution to journal › Article
-
Mark
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : a multicenter IMWG study
(
- Contribution to journal › Article
-
Mark
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone : A pooled analysis
(
- Contribution to journal › Article
-
Mark
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
(
- Contribution to journal › Article
-
Mark
Identification of sequence variants influencing immunoglobulin levels
(
- Contribution to journal › Article
-
Mark
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach
(
- Contribution to journal › Letter
- 2016
-
Mark
Phagocyte Function Decreases after High-Dose Treatment with Melphalan and Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma
(
- Contribution to journal › Article
-
Mark
Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis
(
- Contribution to journal › Article
-
Mark
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010) : A phase 3b study in refractory multiple myeloma
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
(
- Contribution to journal › Article
- 2015
-
Mark
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.
(
- Contribution to journal › Article